Cargando…
DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
Anti-apoptotic Bcl-2-family members are frequently dysregulated in both blood and solid cancers, contributing to their survival despite ongoing oncogenic stress. Yet, such cancer cells often are highly dependent on Bcl-2 for their survival, a feature that is exploited by so-called BH3-mimetic drugs....
Autores principales: | Kerkhofs, Martijn, Vervloessem, Tamara, Stopa, Kinga B., Smith, Victoria M., Vogler, Meike, Bultynck, Geert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408247/ https://www.ncbi.nlm.nih.gov/pubmed/32708132 http://dx.doi.org/10.3390/biom10071081 |
Ejemplares similares
-
Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017) -
Recent advances in uncovering the mechanisms contributing to BIRD-2-induced cell death in B-cell cancer cells
por: Kerkhofs, Martijn, et al.
Publicado: (2019) -
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023) -
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca(2+)‐signalling dysregulation or toxicity in pancreatic acinar cells
por: Jakubowska, Monika A, et al.
Publicado: (2018) -
Inhibition of acylglycerol kinase sensitizes DLBCL to venetoclax via upregulation of FOXO1-mediated BCL-2 expression
por: Ning, Na, et al.
Publicado: (2022)